Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

VUMERITY (diroximel fumarate) for the Treatment of Multiple Sclerosis

Drug Name

VUMERITY™ (diroximel fumarate)

Developer

Biogen and Alkermes

Therapy Class

Fumaric acid esters (novel fumarate)

Product Description

Nuclear factor erythroid-2-related factor 2 activator

Current Indication

Multiple sclerosis (MS)

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top